How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types

(2020) X. Zhao et al.   ANNALS OF ONCOLOGY

Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers

(2019) Konrad Pawelczyk et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer

(2019) Edwin A. Basak et al.   EUROPEAN JOURNAL OF CANCER

Immunotherapy for lung cancer

(2016) Antonius Steven et al.   RESPIROLOGY

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

(2016) Shruti Agrawal et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Chemotherapy is getting ‘smarter’

(2015) Thomas Mehrling   Future Oncology

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

(2015) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Estimating Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer

(2013) Giulia Veronesi et al.   ANNALS OF INTERNAL MEDICINE

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

(2013) S A Quezada et al.   BRITISH JOURNAL OF CANCER

Tumor growth dynamics: insights into evolutionary processes

(2013) Ignacio A. Rodriguez-Brenes et al.   TRENDS IN ECOLOGY & EVOLUTION

Can immuno-oncology offer a truly pan-tumour approach to therapy?

(2012) A. M. M. Eggermont   ANNALS OF ONCOLOGY

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

Performance of computer-aided detection of pulmonary nodules in low-dose CT: comparison with double reading by nodule volume

(2012) Yingru Zhao et al.   EUROPEAN RADIOLOGY

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Are Metastases from Metastases Clinical Relevant? Computer Modelling of Cancer Spread in a Case of Hepatocellular Carcinoma

(2012) Anja Bethge et al.   PLoS One

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

One renegade cancer stem cell?

(2011) Tijana Borovski et al.   CELL CYCLE

Adenosquamous lung carcinomas: A histologic subtype with poor prognosis

(2011) Pier Luigi Filosso et al.   LUNG CANCER

A Perspective on Cancer Cell Metastasis

(2011) C. L. Chaffer et al.   SCIENCE

Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases

(2009) Yun Oh et al.   CANCER

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

(2009) Laurent Claret et al.   JOURNAL OF CLINICAL ONCOLOGY

Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer

(2009) Maaike de Boer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Relevance of Occult Nodal Micrometastases and Circulating Tumor Cells in Colorectal Cancer in a Prospective Multicenter Trial

(2008) K. Koyanagi et al.   CLINICAL CANCER RESEARCH

Comparison of aspects of smoking among the four histological types of lung cancer

(2008) S A Kenfield et al.   TOBACCO CONTROL